BPC-157 vs TB-500: what actually differs

Why this pair gets compared at all

BPC-157 and TB-500 are compared constantly, and the comparison is almost never made on chemical grounds. They are compared because they occupy the same shelf in the research-supply market and because supplier copy has grouped them for years. That is a market fact, not a biological one.

On the chemistry the two have nothing in common. They come from different source proteins, differ in length by 28 residues, were characterised in separate literatures, and act through unrelated proposed mechanisms. Almost every practical difference below follows from those facts rather than from anything either compound is claimed to do.

Origins: a gastric protein fragment and an actin-binding protein

BPC-157 is a synthetic 15-residue sequence corresponding to a portion of a protein identified in gastric juice. The name is an abbreviation of the source protein description, and the numeral is a laboratory designation rather than a version number. It is a fragment: the full source protein is considerably larger and the 15-residue stretch was isolated for study.

Thymosin beta-4, sold as TB-500, is a naturally occurring 43-residue protein with a defined molecular job. It binds monomeric G-actin and holds it in reserve, regulating how much actin is available to polymerise into filaments. That is textbook cell biology, and it is the reason this compound has a mechanism that can be stated in one sentence while most compounds in this market do not.

The mass gap, and why milligrams mislead here

The last two rows are the practically important ones. Vials are sold by mass, but chemistry happens by mole, and these two compounds convert between the two at very different rates. A 5 mg vial of BPC-157 holds about three and a half times as many molecules as a 5 mg vial of TB-500.

Anyone reasoning about these compounds in milligrams is silently comparing unequal amounts of material. The conversion is straightforward arithmetic — moles equal mass divided by molecular weight — and it is worked through in full in the reconstitution and concentration guides.

Different stability failure modes

The single sulfur atom in TB-500's formula is a methionine residue. Methionine is the most oxidation-prone of the twenty amino acids, oxidation adds 16 Da, and on an HPLC trace the oxidised species usually appears as a shoulder on the leading edge of the main peak rather than as a cleanly separated peak. That matters because a shoulder can sit inside a high area-percent figure without ever being counted against it.

BPC-157's sequence contains neither methionine nor cysteine, so that specific route is simply absent. Its stability questions are the ordinary ones for a short peptide: moisture uptake in the lyophilised state, and time spent in solution. Neither compound is exempt from ordinary handling care, but the thing you are watching for differs.

What to check on each COA

• ◆BPC-157: confirm the mass-spectrometry result is near 1419.55 g/mol. A figure near 1400 or well below indicates a truncated or otherwise different sequence than the one the published work used.
• ◆TB-500: confirm the mass is near 4963 g/mol. A result about 42 Da lower is the non-acetylated sequence — a different molecule. A substantially lower result indicates a fragment construct rather than full-length material.
• ◆TB-500: look at the chromatogram itself, not only the purity percentage. Ask whether the main peak is symmetrical or carries a leading shoulder.
• ◆Both: check that the lot number on the certificate matches the lot number on the vial. A generic file name rather than a lot-specific one is a signal the same document is being reused across batches.

The blend question

The two are widely sold as a combined product, and the honest framing of that is commercial rather than scientific. No controlled human study has examined the two administered together, so a blend does not carry more evidence than its components. It carries each component's uncertainty plus the untested interaction between them.

There is also an analytical cost. A blend's certificate has to establish identity and purity for two molecules in one vial, and a single purity figure for a two-component product is a less informative number than two separate figures for two separate vials. If a blend COA reports one percentage without saying which molecule it describes, it has not answered the question.

What the evidence base actually supports

Both compounds' literatures are preclinical. Neither has a completed Phase III trial, and neither is approved for human use in the United States. BPC-157 was additionally placed in the FDA's Category 2 of bulk drug substances, meaning the agency identified significant safety risks for its use in compounding — a regulatory finding of public record, independent of any supplier's purity or manufacturing claims.

A compound can be well-made and still be poorly characterised. Purity describes what is in the vial; it says nothing about what the substance does. No Certificate of Analysis has ever spoken to safety, and that is as true of these two as of anything else in the catalog.